Literature DB >> 7605385

Lp(a) lipoprotein, IgG, IgA and IgM antibodies to Chlamydia pneumoniae and HLA class II genotype in early coronary artery disease.

G H Dahlén1, J Boman, L S Birgander, B Lindblom.   

Abstract

The associations previously found between lipoprotein(a) (Lp(a)) levels and atherosclerotic disorders, diabetes, rheumatoid arthritis and renal diseases suggest that Lp(a) may be involved in autoimmune reactions. The relation found between Lp(a) levels and the HLA class II genotype in males with early coronary artery disease (CAD) further support that assumption. It was suggested that an autoimmune process, perhaps triggered by a concomitant intracellular infection may occur especially in patients with inherited high Lp(a) levels in combination with certain inherited HLA class II genotypes. In this study a Chlamydia pneumoniae IgG titer > or = 32 was significantly more common (P = 0.036) in CAD patients than in matched controls. This is in agreement with previous reports by other investigators. In addition, an IgG titer > or = 256 in combination with an Lp(a) level > or = 120 mg/l was found to occur significantly more often (P = 0.011) in male patients than in male controls. Certain HLA class II DR genotypes in combination with high Lp(a) levels and C. pneumoniae titers occurred more frequently in both male and female patients than in controls. Some combinations were very common in male patients, and the difference in comparison with male controls was highly significant.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7605385     DOI: 10.1016/0021-9150(94)05480-7

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  16 in total

1.  Atherosclerosis due to chronic arteritis caused by Chlamydia pneumoniae: a tentative hypothesis.

Authors:  W Stille; R Dittmann; G Just-Nübling
Journal:  Infection       Date:  1997 Sep-Oct       Impact factor: 3.553

2.  Simplified preparation of human arterial sections for PCR analysis of Chlamydia pneumoniae and human DNA.

Authors:  D Palfrey; P J Cook; J A Smythe; G Y Lip; A V Hine
Journal:  Mol Pathol       Date:  1999-10

Review 3.  Inflammation, infection and atherosclerosis: do antibacterials have a role in the therapy of coronary artery disease?

Authors:  J L Mehta; F Romeo
Journal:  Drugs       Date:  2000-02       Impact factor: 9.546

4.  Rabbit model for Chlamydia pneumoniae infection.

Authors:  I W Fong; B Chiu; E Viira; M W Fong; D Jang; J Mahony
Journal:  J Clin Microbiol       Date:  1997-01       Impact factor: 5.948

5.  Chlamydia pneumoniae infection induces inflammatory changes in the aortas of rabbits.

Authors:  K Laitinen; A Laurila; L Pyhälä; M Leinonen; P Saikku
Journal:  Infect Immun       Date:  1997-11       Impact factor: 3.441

6.  Antibiotic therapy for treatment of Chlamydia to prevent coronary heart disease events.

Authors:  J B Muhlestein
Journal:  Curr Atheroscler Rep       Date:  2000-07       Impact factor: 5.113

Review 7.  Chlamydia pneumoniae and atherosclerosis.

Authors:  Y K Wong; P J Gallagher; M E Ward
Journal:  Heart       Date:  1999-03       Impact factor: 5.994

8.  Chlamydia pneumoniae antibodies are associated with an atherogenic lipid profile.

Authors:  L J Murray; D P O'Reilly; G M Ong; C O'Neill; A E Evans; K B Bamford
Journal:  Heart       Date:  1999-03       Impact factor: 5.994

9.  Association of Chlamydia pneumoniae infection with HLA-B*35 in patients with coronary artery disease.

Authors:  Anil Palikhe; Marja-Liisa Lokki; Pekka Saikku; Maija Leinonen; Mika Paldanius; Mikko Seppänen; Ville Valtonen; Markku S Nieminen; Juha Sinisalo
Journal:  Clin Vaccine Immunol       Date:  2007-11-07

Review 10.  [Arteriosclerosis as a sequela of chronic Chlamydia pneumoniae infection].

Authors:  W Stille; R Dittmann
Journal:  Herz       Date:  1998-05       Impact factor: 1.443

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.